Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BGBA1217 |
Synonyms | |
Therapy Description |
BGBA1217 is a monoclonal antibody that binds to TIGIT and blocks its interaction with Nectin-2 (CD112) and Nectin-like protein 5 (CD155), which results in increased interaction of CD112 and CD155 with the co-stimulatory receptor CD226 and activation of downstream signaling, potentially inducing immune response against tumor cells (NCI Thesaurus, Ann Oncol (2023) 34 (suppl_2): S862). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGBA1217 | BGB-A1217|BGB A1217|Ociperlimab | TIGIT Antibody 19 | BGBA1217 is a monoclonal antibody that binds to TIGIT and blocks its interaction with Nectin-2 (CD112) and Nectin-like protein 5 (CD155), which results in increased interaction of CD112 and CD155 with the co-stimulatory receptor CD226 and activation of downstream signaling, potentially inducing immune response against tumor cells (NCI Thesaurus, Ann Oncol (2023) 34 (suppl_2): S862). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|